163 related articles for article (PubMed ID: 8955651)
1. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
6. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
7. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
Ann Oncol; 1993 Sep; 4(8):673-8. PubMed ID: 8240998
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
